---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261651"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:52:37.686712+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axsome Q3 2025 net product revenue $171M, up 63% YoY; submits sNDA for AXS-05 in Alzheimer's agitation

## Summary
- Total net product revenue $171.0M (63% YoY growth); AUVELITY $136.1M (+69%), SUNOSI $32.8M (+35%), SYMBRAVO $2.1M (first full quarter).
- Net loss narrowed to $47.2M ($0.94/share) from $64.6M ($1.34/share) in Q3 2024; cash $325.3M.
- Submitted sNDA for AXS-05 in Alzheimer's disease agitation (FDA Breakthrough Therapy); plans NDA submission for AXS-12 in narcolepsy in Q4 2025.
- Pipeline: Phase 3 trials to initiate in Q4 2025 for AXS-05 (smoking cessation), solriamfetol (pediatric ADHD, MDD+EDS), and AXS-14 (fibromyalgia).
- AUVELITY prescriptions ~209k in Q3 (+46% YoY); contracted with third large GPO; payer coverage ~85%.

## SEC filing metadata
- accession: 0001193125-25-261651
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/0001193125-25-261651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261651
- JSON: https://secwatch.observer/filing/0001193125-25-261651.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.